Review



cd18  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Miltenyi Biotec cd18
    Antibodies used for analysis of EV surface markers using vesicle flow cytometry.
    Cd18, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 90/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd18/CD18+Antibody%2C+anti-mouse/pmc08037942-5-0-8
    Average 90 stars, based on 10 article reviews
    cd18 - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Genetic Background and Kinetics Define Wound Bed Extracellular Vesicles in a Mouse Model of Cutaneous Injury"

    Article Title: Genetic Background and Kinetics Define Wound Bed Extracellular Vesicles in a Mouse Model of Cutaneous Injury

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms22073551

    Antibodies used for analysis of EV surface markers using vesicle flow cytometry.
    Figure Legend Snippet: Antibodies used for analysis of EV surface markers using vesicle flow cytometry.

    Techniques Used: Cytometry

    Related Articles

    Flow Cytometry:

    Article Title: Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer
    Article Snippet: .. Antibodies for flow cytometry analysis: BV310 anti-CD3, FITC anti-TCRVγ9Vδ2, PE or PeCy5 anti-CD107a, PeCy7 anti-IFNγ, PE anti-TIM3, PE anti-Galectin9, PeCy7 anti-PD1, APC anti-PDL1, PeCy5 anti-CD80, PE anti-CD80, PeCy5 anti-HLAABC, AF647 anti-CD31, PeCy7 anti-CD38, FITC anti-CD226, FITC anti-CD112, FITC anti-CD155, PE anti-LFA1, and isotype controls (BD Biosciences, Pont de Claix, France); BV421 anti-CD69 and isotype control (Miltenyi Biotech, Paris, France); PE anti-HLAE (eBiosciences); PE anti-ULPB2,5,6 (R&D Systems, Minneapolis, USA); APC anti-MICA/B (Biolegend, St-Quentin-en-Yvelines, France); PE anti-ICAM1 and PE anti-ICAM3 (Immunotech, Marseille, France); PE anti-LFA3 (Beckman Coulter, Fullerton, CA, USA). .. Blocking antibodies: anti-BTN3A1 1 h at 10 μg/mL (103.2 clone, kindly gifted by ImCheck Therapeutics, Marseille, France), anti-γδTCR 1 h at 0.5 mg/mL (B1 clone, Biolegend), anti-ICAM1 (W-CAM-1 clone, Thermo fisher, Villebon sur Yvette, France) and anti-CD31 1 h at 10 μg/mL (HEC7 clone, Thermo fisher, Villebon sur Yvette, France).

    Control:

    Article Title: Vγ9Vδ2 T Cells Activation Through Phosphoantigens Can Be Impaired by a RHOB Rerouting in Lung Cancer
    Article Snippet: .. Antibodies for flow cytometry analysis: BV310 anti-CD3, FITC anti-TCRVγ9Vδ2, PE or PeCy5 anti-CD107a, PeCy7 anti-IFNγ, PE anti-TIM3, PE anti-Galectin9, PeCy7 anti-PD1, APC anti-PDL1, PeCy5 anti-CD80, PE anti-CD80, PeCy5 anti-HLAABC, AF647 anti-CD31, PeCy7 anti-CD38, FITC anti-CD226, FITC anti-CD112, FITC anti-CD155, PE anti-LFA1, and isotype controls (BD Biosciences, Pont de Claix, France); BV421 anti-CD69 and isotype control (Miltenyi Biotech, Paris, France); PE anti-HLAE (eBiosciences); PE anti-ULPB2,5,6 (R&D Systems, Minneapolis, USA); APC anti-MICA/B (Biolegend, St-Quentin-en-Yvelines, France); PE anti-ICAM1 and PE anti-ICAM3 (Immunotech, Marseille, France); PE anti-LFA3 (Beckman Coulter, Fullerton, CA, USA). .. Blocking antibodies: anti-BTN3A1 1 h at 10 μg/mL (103.2 clone, kindly gifted by ImCheck Therapeutics, Marseille, France), anti-γδTCR 1 h at 0.5 mg/mL (B1 clone, Biolegend), anti-ICAM1 (W-CAM-1 clone, Thermo fisher, Villebon sur Yvette, France) and anti-CD31 1 h at 10 μg/mL (HEC7 clone, Thermo fisher, Villebon sur Yvette, France).

    Expressing:

    Article Title: Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance
    Article Snippet: MPBCs control and FasL-treated-MPBCs (2 × 10 5 TNCs) were placed in the upper compartments of transwell plates (CA-342, Corning, Corning, NY, USA) and their migration in response to 100 ng/ml human CXCL12/stromal derived factor-1 (SDF1) (350-NS-010, R&D Systems) was tested. .. Chemokine receptor and integrin expression were assessed using anti-CXCR4, anti-LFA1, and anti-VLA4 antibodies (Miltenyi Biotech, Bergisch Gladbach, Germany). ..

    Negative Control:

    Article Title: Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance
    Article Snippet: Intracellular staining was performed using either Inside Stain Kit or FoxP3 Staining Buffer Set (130-090-477 or 130-093-142, respectively, Miltenyi Biotech, Bergisch Gladbach, Germany) according to manufacturer’s instructions. .. The following antibodies were used: anti- mouse CD45 (130-102-412), human CD45 (130-098-143, 130-098-151, 130-098-141, 130-098-148, 130-104-566, 130-110-637), CD34 (130-081-002, 130-090-954), CD90 (130-099-289), CD3 (130-109-460, 130-109-466), CD4 (130-110-680), CD8 (130-109-454), CCR7 (130-108-309), CD45RA (130-108-784, 130-110-637), LFA1 (130-105-437), CD95 (130-104-232), CXCR3 (130-101-378), CCR6 (130-100-377), CD25 (130-109-021), CD33 (130-111-021), CD19 (130-113-642, 130-110-249), CD27 (130-099-499), CD38 (130-108-862), HLA-DR (130-104-825), IL17 (130-100-077), IFN-γ (130-097-944) and FoxP3 (130-098-119) all purchased from Miltenyi Biotech (Bergisch Gladbach, Germany); matched isotype controls were used as negative control. .. Induction of early apoptosis was evaluated using Annexin V and 7-Aminoactinomycin D (7-AAD) (BMS500FI and 00-6993 respectively, Invitrogen, Thermo Fisher Scientific, Waltham MA, USA) staining.

    other:

    Article Title: Genetic Background and Kinetics Define Wound Bed Extracellular Vesicles in a Mouse Model of Cutaneous Injury
    Article Snippet: CD18 , M18/2 , APC , 130-104-019 , Miltenyi Biotec.



    Similar Products

    cd18  (ABclonal Biotechnology)
    92
    ABclonal Biotechnology cd18
    Cd18, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd18/CD18+Rabbit+pAb/pm42625356-108-46-48
    Average 92 stars, based on 1 article reviews
    cd18 - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier
    cell lines hpne dr michel ouellette n a suit 2 dr michel ouellette n a cd18 hpaf ii atcc cat  (ATCC)
    97
    ATCC cell lines hpne dr michel ouellette n a suit 2 dr michel ouellette n a cd18 hpaf ii atcc cat
    Cell Lines Hpne Dr Michel Ouellette N A Suit 2 Dr Michel Ouellette N A Cd18 Hpaf Ii Atcc Cat, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd18/HPAF-II/pm42250222-335-106-119
    Average 97 stars, based on 1 article reviews
    cell lines hpne dr michel ouellette n a suit 2 dr michel ouellette n a cd18 hpaf ii atcc cat - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    ○ cd18 mouse anti dog  (Bio-Rad)
    93
    Bio-Rad ○ cd18 mouse anti dog
    Representative leukocyte-gated histograms illustrating antibody titration for feline leukocyte immunophenotyping. All histograms display singlet leukocytes, defined by FSC-A versus SSC-A morphological gating, followed by FSC—H versus FSC-A singlet discrimination. Titration was performed for <t>CD18,</t> CD21, CD45R, CD4, CD5 and CD8 monoclonal antibodies using three antibody volumes: 10 µL (1:10 dilution), 5.0 µL (1:20 dilution), 3.0 µL (1:33 dilution) and 1.5 µL (1:66 dilution). Minimal working volumes were selected based on optimal signal-to-noise ratios.
    ○ Cd18 Mouse Anti Dog, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd18/Mouse+anti+Dog+CD18/pmc13049955-44-72-79
    Average 93 stars, based on 1 article reviews
    ○ cd18 mouse anti dog - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    cd18  (Developmental Studies Hybridoma Bank)
    94
    Developmental Studies Hybridoma Bank cd18
    Immunoconjugate-mediated capture of HIV-1 from clinical specimens. Five specimens with viral loads ranging from 107,024 to 1,393,440 copies/mL were used. n = 2–3 technical replicates/specimen and n = 3–5 clinical specimens/conjugate, except gp120, gp41, CD45, CD86, ICAM-1, and <t>CD11a/CD18</t> LFA-1 ( n = 1 specimen) were used. A. % Captured HIV-1 by immunoconjugates incubated with HIV-positive plasma. Healthy human plasma acted as a negative control. Beads or isotype controls show nonspecific capture of HIV-1. B. Captured HIV-1 RNA copies by immunoconjugates incubated with 25 μL patient specimens. C. Captured HIV-1 RNA copies by CD46 immunoconjugate incubated with increasing volumes of HIV-positive plasma (ID #1654, VL: 384,000 copies/mL), ranging from 2 to 50 μL ( n = 2–3 technical replicates). D. % Captured HIV-1 by the combination of CD46 and CD44 immunoconjugate incubated with patient plasma (ID #1654, VL: 384,000 copies/mL). CD44 (1.6 mg) and CD46 (1.6 mg) were used alone or in combination (0.8 mg each, total 1.6 mg). The no capture control shows the input copies present in 25 μL of HIV-positive human plasma, measured by RT-qPCR. The isotype control shows nonspecific capture by IgG isotype armed microbeads. No-capture control served as the baseline HIV RNA copies in the different plasma volumes ( n = 1–3 replicates).
    Cd18, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd18/anti-CD18/pmc13177288-47-12-18
    Average 94 stars, based on 1 article reviews
    cd18 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    cd18 ß2 integrin r d systems fab1730r 100ug  (R&D Systems)
    94
    R&D Systems cd18 ß2 integrin r d systems fab1730r 100ug
    Immunoconjugate-mediated capture of HIV-1 from clinical specimens. Five specimens with viral loads ranging from 107,024 to 1,393,440 copies/mL were used. n = 2–3 technical replicates/specimen and n = 3–5 clinical specimens/conjugate, except gp120, gp41, CD45, CD86, ICAM-1, and <t>CD11a/CD18</t> LFA-1 ( n = 1 specimen) were used. A. % Captured HIV-1 by immunoconjugates incubated with HIV-positive plasma. Healthy human plasma acted as a negative control. Beads or isotype controls show nonspecific capture of HIV-1. B. Captured HIV-1 RNA copies by immunoconjugates incubated with 25 μL patient specimens. C. Captured HIV-1 RNA copies by CD46 immunoconjugate incubated with increasing volumes of HIV-positive plasma (ID #1654, VL: 384,000 copies/mL), ranging from 2 to 50 μL ( n = 2–3 technical replicates). D. % Captured HIV-1 by the combination of CD46 and CD44 immunoconjugate incubated with patient plasma (ID #1654, VL: 384,000 copies/mL). CD44 (1.6 mg) and CD46 (1.6 mg) were used alone or in combination (0.8 mg each, total 1.6 mg). The no capture control shows the input copies present in 25 μL of HIV-positive human plasma, measured by RT-qPCR. The isotype control shows nonspecific capture by IgG isotype armed microbeads. No-capture control served as the baseline HIV RNA copies in the different plasma volumes ( n = 1–3 replicates).
    Cd18 ß2 Integrin R D Systems Fab1730r 100ug, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd18/Human+Integrin+beta+2%2FCD18+Alexa+Fluor%C2%AE+647-conjugated+Antibody/pm41863801-143-220-222
    Average 94 stars, based on 1 article reviews
    cd18 ß2 integrin r d systems fab1730r 100ug - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    cd18  (Proteintech)
    94
    Proteintech cd18
    Immunoconjugate-mediated capture of HIV-1 from clinical specimens. Five specimens with viral loads ranging from 107,024 to 1,393,440 copies/mL were used. n = 2–3 technical replicates/specimen and n = 3–5 clinical specimens/conjugate, except gp120, gp41, CD45, CD86, ICAM-1, and <t>CD11a/CD18</t> LFA-1 ( n = 1 specimen) were used. A. % Captured HIV-1 by immunoconjugates incubated with HIV-positive plasma. Healthy human plasma acted as a negative control. Beads or isotype controls show nonspecific capture of HIV-1. B. Captured HIV-1 RNA copies by immunoconjugates incubated with 25 μL patient specimens. C. Captured HIV-1 RNA copies by CD46 immunoconjugate incubated with increasing volumes of HIV-positive plasma (ID #1654, VL: 384,000 copies/mL), ranging from 2 to 50 μL ( n = 2–3 technical replicates). D. % Captured HIV-1 by the combination of CD46 and CD44 immunoconjugate incubated with patient plasma (ID #1654, VL: 384,000 copies/mL). CD44 (1.6 mg) and CD46 (1.6 mg) were used alone or in combination (0.8 mg each, total 1.6 mg). The no capture control shows the input copies present in 25 μL of HIV-positive human plasma, measured by RT-qPCR. The isotype control shows nonspecific capture by IgG isotype armed microbeads. No-capture control served as the baseline HIV RNA copies in the different plasma volumes ( n = 1–3 replicates).
    Cd18, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd18/CD18+Fusion+Protein/pm41831321-247-67-68
    Average 94 stars, based on 1 article reviews
    cd18 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    itgb2 cd18 agonist leukadherin 1  (MedChemExpress)
    94
    MedChemExpress itgb2 cd18 agonist leukadherin 1
    Immunoconjugate-mediated capture of HIV-1 from clinical specimens. Five specimens with viral loads ranging from 107,024 to 1,393,440 copies/mL were used. n = 2–3 technical replicates/specimen and n = 3–5 clinical specimens/conjugate, except gp120, gp41, CD45, CD86, ICAM-1, and <t>CD11a/CD18</t> LFA-1 ( n = 1 specimen) were used. A. % Captured HIV-1 by immunoconjugates incubated with HIV-positive plasma. Healthy human plasma acted as a negative control. Beads or isotype controls show nonspecific capture of HIV-1. B. Captured HIV-1 RNA copies by immunoconjugates incubated with 25 μL patient specimens. C. Captured HIV-1 RNA copies by CD46 immunoconjugate incubated with increasing volumes of HIV-positive plasma (ID #1654, VL: 384,000 copies/mL), ranging from 2 to 50 μL ( n = 2–3 technical replicates). D. % Captured HIV-1 by the combination of CD46 and CD44 immunoconjugate incubated with patient plasma (ID #1654, VL: 384,000 copies/mL). CD44 (1.6 mg) and CD46 (1.6 mg) were used alone or in combination (0.8 mg each, total 1.6 mg). The no capture control shows the input copies present in 25 μL of HIV-positive human plasma, measured by RT-qPCR. The isotype control shows nonspecific capture by IgG isotype armed microbeads. No-capture control served as the baseline HIV RNA copies in the different plasma volumes ( n = 1–3 replicates).
    Itgb2 Cd18 Agonist Leukadherin 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd18/Leukadherin-1/pm41824786-251-9-12
    Average 94 stars, based on 1 article reviews
    itgb2 cd18 agonist leukadherin 1 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti integrin blocking β2 cd18 antibody  (Merck & Co)
    86
    Merck & Co anti integrin blocking β2 cd18 antibody
    Immunoconjugate-mediated capture of HIV-1 from clinical specimens. Five specimens with viral loads ranging from 107,024 to 1,393,440 copies/mL were used. n = 2–3 technical replicates/specimen and n = 3–5 clinical specimens/conjugate, except gp120, gp41, CD45, CD86, ICAM-1, and <t>CD11a/CD18</t> LFA-1 ( n = 1 specimen) were used. A. % Captured HIV-1 by immunoconjugates incubated with HIV-positive plasma. Healthy human plasma acted as a negative control. Beads or isotype controls show nonspecific capture of HIV-1. B. Captured HIV-1 RNA copies by immunoconjugates incubated with 25 μL patient specimens. C. Captured HIV-1 RNA copies by CD46 immunoconjugate incubated with increasing volumes of HIV-positive plasma (ID #1654, VL: 384,000 copies/mL), ranging from 2 to 50 μL ( n = 2–3 technical replicates). D. % Captured HIV-1 by the combination of CD46 and CD44 immunoconjugate incubated with patient plasma (ID #1654, VL: 384,000 copies/mL). CD44 (1.6 mg) and CD46 (1.6 mg) were used alone or in combination (0.8 mg each, total 1.6 mg). The no capture control shows the input copies present in 25 μL of HIV-positive human plasma, measured by RT-qPCR. The isotype control shows nonspecific capture by IgG isotype armed microbeads. No-capture control served as the baseline HIV RNA copies in the different plasma volumes ( n = 1–3 replicates).
    Anti Integrin Blocking β2 Cd18 Antibody, supplied by Merck & Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd18/anti+cd18+chinleric+reco133binant/pm41805568-344-83-89
    Average 86 stars, based on 1 article reviews
    anti integrin blocking β2 cd18 antibody - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    o cd18 mouse anti dog  (Bio-Rad)
    93
    Bio-Rad o cd18 mouse anti dog
    Immunoconjugate-mediated capture of HIV-1 from clinical specimens. Five specimens with viral loads ranging from 107,024 to 1,393,440 copies/mL were used. n = 2–3 technical replicates/specimen and n = 3–5 clinical specimens/conjugate, except gp120, gp41, CD45, CD86, ICAM-1, and <t>CD11a/CD18</t> LFA-1 ( n = 1 specimen) were used. A. % Captured HIV-1 by immunoconjugates incubated with HIV-positive plasma. Healthy human plasma acted as a negative control. Beads or isotype controls show nonspecific capture of HIV-1. B. Captured HIV-1 RNA copies by immunoconjugates incubated with 25 μL patient specimens. C. Captured HIV-1 RNA copies by CD46 immunoconjugate incubated with increasing volumes of HIV-positive plasma (ID #1654, VL: 384,000 copies/mL), ranging from 2 to 50 μL ( n = 2–3 technical replicates). D. % Captured HIV-1 by the combination of CD46 and CD44 immunoconjugate incubated with patient plasma (ID #1654, VL: 384,000 copies/mL). CD44 (1.6 mg) and CD46 (1.6 mg) were used alone or in combination (0.8 mg each, total 1.6 mg). The no capture control shows the input copies present in 25 μL of HIV-positive human plasma, measured by RT-qPCR. The isotype control shows nonspecific capture by IgG isotype armed microbeads. No-capture control served as the baseline HIV RNA copies in the different plasma volumes ( n = 1–3 replicates).
    O Cd18 Mouse Anti Dog, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd18/Mouse+anti+Dog+CD18/10__1016_slash_j__mex__2026__103869-52-72-79
    Average 93 stars, based on 1 article reviews
    o cd18 mouse anti dog - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Representative leukocyte-gated histograms illustrating antibody titration for feline leukocyte immunophenotyping. All histograms display singlet leukocytes, defined by FSC-A versus SSC-A morphological gating, followed by FSC—H versus FSC-A singlet discrimination. Titration was performed for CD18, CD21, CD45R, CD4, CD5 and CD8 monoclonal antibodies using three antibody volumes: 10 µL (1:10 dilution), 5.0 µL (1:20 dilution), 3.0 µL (1:33 dilution) and 1.5 µL (1:66 dilution). Minimal working volumes were selected based on optimal signal-to-noise ratios.

    Journal: MethodsX

    Article Title: Feline leukocyte immunophenotyping: an optimised whole-blood flow cytometry protocol

    doi: 10.1016/j.mex.2026.103869

    Figure Lengend Snippet: Representative leukocyte-gated histograms illustrating antibody titration for feline leukocyte immunophenotyping. All histograms display singlet leukocytes, defined by FSC-A versus SSC-A morphological gating, followed by FSC—H versus FSC-A singlet discrimination. Titration was performed for CD18, CD21, CD45R, CD4, CD5 and CD8 monoclonal antibodies using three antibody volumes: 10 µL (1:10 dilution), 5.0 µL (1:20 dilution), 3.0 µL (1:33 dilution) and 1.5 µL (1:66 dilution). Minimal working volumes were selected based on optimal signal-to-noise ratios.

    Article Snippet: Step 2 – Leukocytes extracellular staining Materials • EDTA Whole blood sample ± Transfix® • 200 μl pipettes • 100 μl pipettes • 10 μl pipettes • Flow cytometry tubes • Permanent marker • Cytometer tube rack Reagents • Monoclonal antibodies: ○ CD5 Anti-cat – clone FE1.1B11 (BIO-RAD®) ○ CD4 Anti-cat – clone vpg34 (BIO-RAD®) ○ CD8 Anti-cat alpha/beta purified – clone vpg9 (BIO-RAD®) ○ Rat Anti-Mouse IgG1 – clone X56 (BIO-RAD®) ○ CD18 Mouse Anti-Dog – clone CA1.4E9 (BIO-RAD®) ○ CD21 Mouse Anti-Dog – clone CA2.1D6 (BIO-RAD®) ○ CD45R Rat Anti-Mouse – clone RA3–6B2 (BIO-RAD®) • 10x Red blood cells (RBC) lysis buffer solution (BD FACSTM lysing solution) • PBS 1% solution Equipment • Countess TM 3 (Thermo Fisher Scientific, USA) • Freezer • Dark incubation chamber • Timer • Vortex (MX-S®, China) • Centrifuge (model 5810R, Eppendorf®, Germany) • Flow cytometry analyser BD FACSCanto II (Becton Dickinson (BD), San Jose, USA) Methods 1.

    Techniques: Titration, Bioprocessing

    Immunoconjugate-mediated capture of HIV-1 from clinical specimens. Five specimens with viral loads ranging from 107,024 to 1,393,440 copies/mL were used. n = 2–3 technical replicates/specimen and n = 3–5 clinical specimens/conjugate, except gp120, gp41, CD45, CD86, ICAM-1, and CD11a/CD18 LFA-1 ( n = 1 specimen) were used. A. % Captured HIV-1 by immunoconjugates incubated with HIV-positive plasma. Healthy human plasma acted as a negative control. Beads or isotype controls show nonspecific capture of HIV-1. B. Captured HIV-1 RNA copies by immunoconjugates incubated with 25 μL patient specimens. C. Captured HIV-1 RNA copies by CD46 immunoconjugate incubated with increasing volumes of HIV-positive plasma (ID #1654, VL: 384,000 copies/mL), ranging from 2 to 50 μL ( n = 2–3 technical replicates). D. % Captured HIV-1 by the combination of CD46 and CD44 immunoconjugate incubated with patient plasma (ID #1654, VL: 384,000 copies/mL). CD44 (1.6 mg) and CD46 (1.6 mg) were used alone or in combination (0.8 mg each, total 1.6 mg). The no capture control shows the input copies present in 25 μL of HIV-positive human plasma, measured by RT-qPCR. The isotype control shows nonspecific capture by IgG isotype armed microbeads. No-capture control served as the baseline HIV RNA copies in the different plasma volumes ( n = 1–3 replicates).

    Journal: Analytical Chemistry

    Article Title: Immunomagnetic Sample Preparation Targeting Host- and Viral-Derived Antigens for HIV‑1 Isolation from Limited Plasma Volumes

    doi: 10.1021/acs.analchem.5c06176

    Figure Lengend Snippet: Immunoconjugate-mediated capture of HIV-1 from clinical specimens. Five specimens with viral loads ranging from 107,024 to 1,393,440 copies/mL were used. n = 2–3 technical replicates/specimen and n = 3–5 clinical specimens/conjugate, except gp120, gp41, CD45, CD86, ICAM-1, and CD11a/CD18 LFA-1 ( n = 1 specimen) were used. A. % Captured HIV-1 by immunoconjugates incubated with HIV-positive plasma. Healthy human plasma acted as a negative control. Beads or isotype controls show nonspecific capture of HIV-1. B. Captured HIV-1 RNA copies by immunoconjugates incubated with 25 μL patient specimens. C. Captured HIV-1 RNA copies by CD46 immunoconjugate incubated with increasing volumes of HIV-positive plasma (ID #1654, VL: 384,000 copies/mL), ranging from 2 to 50 μL ( n = 2–3 technical replicates). D. % Captured HIV-1 by the combination of CD46 and CD44 immunoconjugate incubated with patient plasma (ID #1654, VL: 384,000 copies/mL). CD44 (1.6 mg) and CD46 (1.6 mg) were used alone or in combination (0.8 mg each, total 1.6 mg). The no capture control shows the input copies present in 25 μL of HIV-positive human plasma, measured by RT-qPCR. The isotype control shows nonspecific capture by IgG isotype armed microbeads. No-capture control served as the baseline HIV RNA copies in the different plasma volumes ( n = 1–3 replicates).

    Article Snippet: Mouse IgG antibodies: CD8 (UCH-T4), Cat # sc-1181, Santa Cruz Biotechnology, Inc.; CD18 (Integrin beta-2), Clone ID H52-s, DSHB (Developmental Studies Hybridoma Bank); HIV1gp120, Cat # sc-57810, Santa Cruz Biotechnology, Inc.; CD26, Cat # 555435, BD Pharmingen; integrin alpha-4, Clone ID P4G9, DSHB; CD43 (DF-T1), Cat # sc-6256, Santa Cruz Biotechnology, Inc.; CD46 (1E3D1), Cat # MA5-29113, Invitrogen; β 2 -microglobulin (B2M-01), Cat # MA1–19141, Invitrogen; integrin alpha-L (CD11a), Clone ID MHM.24, DSHB; CD86 (B7-2), Clone ID IT2.2, Invitrogen; CD44, Clone ID H4C4, DSHB; ICAM1, Clone ID P2A4, DSHB; CD45, Clone ID H5A5, DSHB; HLA-DR, Clone ID LN3, Cat # 14-9956-82, Thermo Fisher Scientific; Tim-4 (human):Fc (mouse) (rec.), Cat # CHI-HF-211T4-C100, AdipoGen Life Sciences.

    Techniques: Incubation, Clinical Proteomics, Negative Control, Control, Quantitative RT-PCR